AR027815A1 - Formulacion farmaceutica y metodo para su produccion - Google Patents

Formulacion farmaceutica y metodo para su produccion

Info

Publication number
AR027815A1
AR027815A1 ARP990105734A ARP990105734A AR027815A1 AR 027815 A1 AR027815 A1 AR 027815A1 AR P990105734 A ARP990105734 A AR P990105734A AR P990105734 A ARP990105734 A AR P990105734A AR 027815 A1 AR027815 A1 AR 027815A1
Authority
AR
Argentina
Prior art keywords
production
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
ARP990105734A
Other languages
English (en)
Original Assignee
Pharamcia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR027815(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/en
Application filed by Pharamcia & Upjohn Ab filed Critical Pharamcia & Upjohn Ab
Publication of AR027815A1 publication Critical patent/AR027815A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP990105734A 1998-11-11 1999-11-11 Formulacion farmaceutica y metodo para su produccion AR027815A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (1)

Publication Number Publication Date
AR027815A1 true AR027815A1 (es) 2003-04-16

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105734A AR027815A1 (es) 1998-11-11 1999-11-11 Formulacion farmaceutica y metodo para su produccion

Country Status (40)

Country Link
US (1) US6911217B1 (es)
EP (1) EP1128819B1 (es)
JP (1) JP3616011B2 (es)
KR (1) KR100467384B1 (es)
CN (1) CN1169522C (es)
AP (1) AP1323A (es)
AR (1) AR027815A1 (es)
AT (1) ATE247458T1 (es)
AU (1) AU762410B2 (es)
BG (1) BG65149B1 (es)
BR (1) BRPI9915142B8 (es)
CA (1) CA2350061C (es)
CZ (1) CZ299582B6 (es)
DE (1) DE69910604T2 (es)
DK (1) DK1128819T3 (es)
EA (1) EA005074B1 (es)
EE (1) EE05232B1 (es)
ES (1) ES2204193T3 (es)
GE (1) GEP20022833B (es)
HK (1) HK1040917B (es)
HR (1) HRP20010333B1 (es)
HU (1) HU226582B1 (es)
ID (1) ID30039A (es)
IL (1) IL142809A0 (es)
IS (1) IS2370B (es)
MA (1) MA25325A1 (es)
MY (1) MY122195A (es)
NO (1) NO331399B1 (es)
NZ (1) NZ511430A (es)
OA (1) OA11673A (es)
PL (1) PL195780B1 (es)
PT (1) PT1128819E (es)
RS (1) RS49891B (es)
SE (1) SE9803871D0 (es)
SI (1) SI1128819T1 (es)
SK (1) SK284758B6 (es)
TW (2) TWI267385B (es)
UA (1) UA57165C2 (es)
WO (1) WO2000027364A1 (es)
ZA (1) ZA200103575B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
CZ304671B6 (cs) 1999-11-11 2014-08-27 Pharmacia Ab Farmaceutický prostředek obsahující tolterodin a jeho použití
CA2496806A1 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Oral liquid tolterodine composition
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
ES2324712T5 (es) * 2003-01-22 2012-06-08 Pfizer Health Ab Dosis reducida de tolterodina para tratar trastornos urinarios
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
DK2210605T3 (en) 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
JP4771956B2 (ja) 2003-11-04 2011-09-14 スパーナス ファーマシューティカルズ インコーポレイテッド バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (en) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
TW200640839A (en) * 2005-01-10 2006-12-01 Teva Pharma Process for preparing Tolterodine tartrate
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
TR201902010T4 (tr) 2006-01-18 2019-03-21 Intec Pharma Ltd Bir ajanın oral alımına yönelik taşıyıcı cihaz.
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
JP2009527554A (ja) * 2006-02-24 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド コハク酸メトプロロールｅ．ｒ．の錠剤およびその調製方法
JP2009530397A (ja) * 2006-03-21 2009-08-27 テバ ファーマシューティカル インダストリーズ リミティド トルテロジンの調節された開放性製剤
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
WO2007112581A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
EP3542792B1 (en) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Controlled release 25-hydroxyvitamin d
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
EP2173329A1 (en) * 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
ES2692437T3 (es) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
WO2009140557A2 (en) * 2008-05-14 2009-11-19 Capricorn Pharma, Inc. Modified release tolterodine formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
CA2769760A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
HUE048464T2 (hu) 2010-03-29 2020-07-28 Opko Ireland Global Holdings Ltd Módszerek és készítmények mellékpajzsmirigy szintjének csökkentésére
PL2552418T3 (pl) 2010-03-29 2017-12-29 Ferring B.V. Szybko rozpuszczająca się kompozycja farmaceutyczna
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120289560A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2013037708A1 (en) 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
WO2013047795A1 (ja) * 2011-09-30 2013-04-04 アステラス製薬株式会社 粒子状医薬組成物
EP2872177B1 (en) 2012-07-12 2017-12-20 Ferring BV Diclofenac formulations
MX2015003658A (es) * 2012-09-20 2015-09-25 Ohr Pharma Llc Microparticulas biodegradables de capas multiples para la liberacion sostenida de agentes terapeuticos.
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
EP2968579B1 (en) * 2013-03-13 2020-04-15 Intervet International B.V. Stable bioactive substances and methods of making
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
CA2957240A1 (en) 2014-08-07 2016-02-11 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2902911C (en) * 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20190083628A1 (en) * 2016-02-23 2019-03-21 Nipro Corporation Pharmaceutical composition particles and orally disintegrating preparation including the same
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
KR100467384B1 (ko) 2005-01-24
BG105582A (en) 2001-12-29
SK6252001A3 (en) 2002-01-07
EP1128819A1 (en) 2001-09-05
ATE247458T1 (de) 2003-09-15
CA2350061A1 (en) 2000-05-18
EE200100254A (et) 2002-12-16
TWI222879B (en) 2004-11-01
NO20012314D0 (no) 2001-05-10
RS49891B (sr) 2008-08-07
ZA200103575B (en) 2002-05-03
MA25325A1 (fr) 2001-12-31
SK284758B6 (sk) 2005-11-03
HK1040917B (zh) 2005-05-27
DE69910604D1 (de) 2003-09-25
BRPI9915142B8 (pt) 2021-05-25
SI1128819T1 (en) 2003-12-31
AP1323A (en) 2004-11-05
EA200100538A1 (ru) 2001-10-22
MY122195A (en) 2006-03-31
CZ299582B6 (cs) 2008-09-10
DK1128819T3 (da) 2003-12-01
PL195780B1 (pl) 2007-10-31
JP3616011B2 (ja) 2005-02-02
YU33101A (sh) 2003-10-31
EE05232B1 (et) 2009-12-15
PL348612A1 (en) 2002-06-03
TWI267385B (en) 2006-12-01
DE69910604T2 (de) 2004-06-24
HRP20010333B1 (en) 2004-10-31
GEP20022833B (en) 2002-11-25
WO2000027364A1 (en) 2000-05-18
NO331399B1 (no) 2011-12-19
UA57165C2 (uk) 2003-06-16
HUP0105038A2 (en) 2002-06-29
AU762410B2 (en) 2003-06-26
EP1128819B1 (en) 2003-08-20
CZ20011627A3 (cs) 2001-10-17
SE9803871D0 (sv) 1998-11-11
CN1169522C (zh) 2004-10-06
BR9915142A (pt) 2001-08-07
CA2350061C (en) 2005-05-17
BRPI9915142B1 (pt) 2015-08-25
CN1326339A (zh) 2001-12-12
AP2001002166A0 (en) 2001-06-30
HRP20010333A2 (en) 2003-04-30
BG65149B1 (bg) 2007-04-30
NO20012314L (no) 2001-07-09
JP2003517446A (ja) 2003-05-27
HUP0105038A3 (en) 2006-07-28
IS5936A (is) 2001-05-09
PT1128819E (pt) 2003-12-31
NZ511430A (en) 2003-05-30
ES2204193T3 (es) 2004-04-16
HK1040917A1 (en) 2002-06-28
IS2370B (is) 2008-06-15
KR20010075695A (ko) 2001-08-09
IL142809A0 (en) 2002-03-10
US6911217B1 (en) 2005-06-28
EA005074B1 (ru) 2004-10-28
OA11673A (en) 2005-01-12
ID30039A (id) 2001-11-01
HU226582B1 (en) 2009-04-28
AU1436600A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
AR027815A1 (es) Formulacion farmaceutica y metodo para su produccion
BR9711218A (pt) Composi-Æo eletrodeposit vel m-todo para sua produ-Æo e substrato
NO20012915D0 (no) Ny farmasöytisk formulering
DK1073417T3 (da) Farmaceutisk aerosolformulering
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
ATE464050T1 (de) Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
NO992339D0 (no) Farmas°ytiske formuleringer
NO20022086D0 (no) Antidiabetisk formulering og fremgangsmåte
DE60002893D1 (de) Computerplattformen und deren betriebsverfahren
ID24654A (id) Formulasi farmasi omeprazola
NO20016277D0 (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske formuleringer
PT1194051E (pt) Metodo e dispositivo para produzir escovas e escovas produzidas usando o mesmo
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
FI20012462A (fi) Farmaseuttisia formulaatioita ja menetelmiä käsittäen intranasaalista morfiinia
DE60001758D1 (de) Radarverfahren und vorrichtungen
DK1128831T3 (da) Farmaceutisk moxifloxacinpræparat
LV12624A (lv) Thienylazolylalcoxyethanamines their preparation and their application as medicaments
BR9708336A (pt) Diidrato de eprosartan e processo para sua produção e formulação
PT1140824E (pt) Metodo para producao de 3-alcanoilindolos e 3-alquilindolos
TR199801871A3 (tr) Bifenilsulfonilsiyanamidler üretim yöntemi ve ilaç olarak kullanimlari.
FI20010075A (fi) Terveysvaikutteinen tuote ja menetelmä
DE60033759D1 (de) Destillationsapparat und Destillationsmethode
FI19992513A (fi) Menetelmä ja laite rullanvaihdossa
FI19992112A (fi) Synkronointimenetelmä ja -järjestely
DE60025502D1 (de) Sic-einkristall und herstellungsverfahren dafür

Legal Events

Date Code Title Description
FG Grant, registration